ストックスクリーナーアプリを入手
6.50
4.00%
0.25
アフターアワーズ：
6.50
前日終値:
$6.25
開ける：
$6.25
24時間の取引高:
163.14K
Relative Volume:
1.00
時価総額：
$224.09M
収益：
$44.64M
当期純損益:
$-10.10M
株価収益率:
-18.90
EPS:
-0.344
ネットキャッシュフロー:
$-14.45M
1週間 パフォーマンス:
+0.15%
1か月 パフォーマンス:
-13.56%
6か月 パフォーマンス:
-25.80%
1年 パフォーマンス:
+23.81%
1日の値動き範囲:
$6.25
$6.535
1週間の範囲:
$5.65
$6.54
52週間の値動き範囲:
$5.02
$9.92
Fennec Pharmaceuticals Inc Stock (FENC) Company Profile
名前
Fennec Pharmaceuticals Inc
セクター
電話
(919) 636-4530
住所
PO BOX 13628, RESEARCH TRIANGLE PARK, NC
Compare FENC vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FENC
Fennec Pharmaceuticals Inc
|
6.50 | 215.47M | 44.64M | -10.10M | -14.45M | -0.344 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-12 | 開始されました | B. Riley Securities | Buy |
| 2026-01-09 | 開始されました | Piper Sandler | Overweight |
| 2022-11-22 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2022-09-07 | 開始されました | CapitalOne | Overweight |
| 2022-08-08 | 再開されました | Craig Hallum | Buy |
| 2020-06-05 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-10-11 | 開始されました | Goldman | Buy |
すべてを表示
Fennec Pharmaceuticals Inc (FENC) 最新ニュース
(FRX) Trading Report (FRX:CA) - Stock Traders Daily
Treasury Yields: Can Fennec Pharmaceuticals Inc stock outperform in a bear market2026 Reactions & Verified Entry Point Detection - baoquankhu1.vn
US Market Recap: What is the long term forecast for Fennec Pharmaceuticals Inc stock2026 Key Lessons & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Stock Recap: Can Fennec Pharmaceuticals Inc expand its profit marginsGap Up & Low Risk High Reward Ideas - baoquankhu1.vn
FRX.CA Forecast, Price Target & Analyst Ratings | FENNEC PHARMACEUTICALS INC (TSX:FRX) - ChartMill
Aug Spikes: Why is Fennec Pharmaceuticals Inc stock going down2026 Macro Impact & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and Fennec Pharmaceuticals (FENC) - The Globe and Mail
H.C. Wainwright reiterates Fennec Pharmaceuticals stock rating on expanded study - Investing.com
Fennec Pharmaceuticals Announces New Investigator-Sponsored Study of PEDMARK® for Preventing Cisplatin-Induced Hearing Loss in AYA and Adult Cancer Patients - Minichart
Fennec Pharmaceuticals Inc. (FENC) stock price, news, quote and history - Yahoo Finance UK
Fennec Pharmaceuticals: University of Arizona launches PEDMARK study in AYA and adult cisplatin patients - TradingView — Track All Markets
Fennec (FENC) backs new University of Arizona study on PEDMARK use in cisplatin-treated patients - Stock Titan
Fennec Pharmaceuticals Inc. Announces Investigator-Sponsored Study of PEDMARK in AYA and Adult Patients With Solid Tumors Receiving Cisplatin - marketscreener.com
Fennec Pharmaceuticals urges focus on community and science to shape a healthier world - Traders Union
Fennec Pharmaceuticals: University Of Arizona Cancer Center Investigator-Sponsored Study Advances PEDMARK In AYA And Adult Cancer Patients - Pulse 2.0
FENC Technical Analysis & Stock Price Forecast - Intellectia AI
Fennec Backs New PEDMARK Study Expanding Cisplatin Ototoxicity Research to Adult Cancers - TipRanks
Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center - Bitget
Can a hearing-loss drug help more adults on cisplatin? Arizona study starts - Stock Titan
Trend Recap: Can Fennec Pharmaceuticals Inc sustain earnings growth2026 Short Interest & Step-by-Step Swing Trade Plans - baoquankhu1.vn
(FENC) Risk Channels and Responsive Allocation - Stock Traders Daily
FENC Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Adherex Technologies (NASDAQ:FENC) Cut to Hold at Wall Street Zen - MarketBeat
Adherex Technologies (NASDAQ:FENC) Director Rosty Raykov Sells 10,946 Shares - MarketBeat
[Form 4] FENNEC PHARMACEUTICALS INC. Insider Trading Activity - Stock Titan
Fennec (FENC) CEO gets 200,000 options and new common shares - Stock Titan
FENNEC (FENC) director exercises 15,598 options and sells shares under 10b5-1 plan - Stock Titan
CMO at Fennec (NASDAQ: FENC) receives 120,000 stock options award - Stock Titan
Fennec (NASDAQ: FENC) CCO gets 120,000 options, 20,679 shares - Stock Titan
Public market insider net buying at Fennec Pharmaceuticals (FRX) - The Globe and Mail
FENC (NASDAQ) insider sale notice: 10,946 shares via option exercise - Stock Titan
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
HC Wainwright Has Bearish Forecast for FENC Q1 Earnings - MarketBeat
Equities Analysts Offer Predictions for TSE:FRX Q1 Earnings - MarketBeat
Adherex Technologies Inc. (NASDAQ:FENC) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Research Analysts Set Expectations for TSE:FRX Q3 Earnings - Defense World
Aug Ideas: Does Fennec Pharmaceuticals Inc have a competitive edge2026 Trade Ideas & Long-Term Growth Plans - baoquankhu1.vn
Fennec Pharmaceuticals earnings are imminent; these most accurate analysts revise forecasts ahead of earnings call - MSN
CEO Moves: Can Fennec Pharmaceuticals Inc expand its profit marginsWeekly Trade Analysis & Risk Controlled Daily Plans - baoquankhu1.vn
HC Wainwright Issues Negative Forecast for FENC Earnings - MarketBeat
24 new Fennec hires get options at $5.77 under Nasdaq rule - Stock Titan
Can Fennec Pharmaceuticals Inc stock double in the next yearStock Surge & Accurate Intraday Trade Tips - baoquankhu1.vn
Income Plays: Does Fennec Pharmaceuticals Inc have a sustainable dividend2026 Fed Impact & High Return Stock Watch Alerts - baoquankhu1.vn
Fennec Pharmaceuticals 2025 Annual Report: PEDMARK® Commercialization, Risks, and Intellectual Property Overview - Minichart
Adherex Technologies (NASDAQ:FENC) Cut to Strong Sell at Zacks Research - Defense World
Fennec Posts Record PEDMARK Sales in 2025 as Clinical and Commercial Momentum Builds - TipRanks
Fennec Pharmaceuticals 2025 10-K: Revenue $44.6M, Net Loss $(9.7)M - TradingView
Fennec (NASDAQ: FENC) expands PEDMARK reach and delays generic entry - stocktitan.net
Adherex Technologies (NASDAQ:FENC) Lowered to "Strong Sell" Rating by Zacks Research - MarketBeat
Fennec Pharmaceuticals (TSE:FRX) Stock Passes Below 50-Day Moving AverageShould You Sell? - MarketBeat
Fennec (NASDAQ: FENC) CFO exercises 13,072 stock options in Form 4 - Stock Titan
Fennec Pharmaceuticals Inc (FENC) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):